Britain’s medicines agency strengthened warnings on antidepressants this week. The new, stronger warnings were prompted by a review of selective serotonin re-uptake inhibitors that caused major concern among doctors and patients. The Medicines and Healthcare Products Regulatory Agency (MHRA) said there should be tougher warnings regarding the threat of withdrawal for a patient who has recently ceased treatment involving SSRI’s. The MHRA has suggested to patients and doctors that the lowest recommended dose should be prescribed to avoid such reactions.

As a result of the review the MHRA went on to suggest that doctors closely monitor young adults as a preventive action when SSRI’s are involved with the treatment. The assigned a group of experts to investigate the drugs safety after the claims that SSRI’s increase suicidal thoughts and tendencies of those on it. Some patients also reported un-wanted withdrawal effects when they came off treatment.

The MHRA is also investigating GlaxoSmithKline on charges that the drug giant withheld important clinical data on the suicide risk of teenagers who took the drug Seroxat.

Comments are closed.